Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy
View Full Paper
Ask AI
Bookmark
Share
Key result
Drug-induced long QT syndrome is primarily caused by drugs that block the human ERG (hERG) potassium channel, with the risk of torsades de pointes increased in females, patients with heart disease, and those with hypokalemia.
Population
Patients at risk for or presenting with drug-induced long QT syndrome and torsades de pointes
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May inform safer prescribing around hERG blockers in females and hypokalemic patients; confirms mechanisms while leaving open personalized risk models.
Structured PICO
P
Population
Patients at risk for or presenting with drug-induced long QT syndrome and torsades de pointes
E
Exposure
Administration of QT interval prolonging drugs (including anti-arrhythmics, antibiotics, neurotropics, antifungals, and antimalarials)
Drug-induced long QT syndrome is a potentially lethal iatrogenic channelopathy primarily caused by hERG channel blockade, requiring careful risk stratification and avoidance of interacting QT-prolonging drugs.
Limitations
- Underreporting bias in pharmacovigilance data
- Lack of clinical trials supporting specific ECG monitoring recommendations
- Genetic tests for identifying high-risk patients are not yet available
Cite This Study
Abriel et al. (2004) conducted a review in Drug-induced long QT syndrome. QT interval prolonging drugs was evaluated. Drug-induced long QT syndrome is primarily caused by drugs that block the human ERG (hERG) potassium channel, with the risk of torsades de pointes increased in females, patients with heart disease, and those with hypokalemia.
View Full Paper
Ask AI
Bookmark
Share